Deep liver testing study for cancer and non-cancer liver disease
Part of Cancer, Digestive system clinical trials.
This study looks closely at how the liver’s immune system and disease processes work in people with liver problems, including some with suspected or confirmed liver/bile duct cancer. You may also be offered a liver needle sample (FNA) if it’s safe for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can read and sign an informed consent form, or have consent provided appropriately.
- You are between 18 and 75 years old.
- You have a liver-related condition: either suspected/confirmed liver or bile duct cancer, or confirmed long-term (chronic) non-cancer liver/bile disease.
- If you are offered the optional liver needle sample: you agree to an ultrasound-guided liver FNA.
- If doing FNA: you had a liver/upper abdomen scan (ultrasound/CT/MRI) within the last 12 months, and blood tests for blood counts and clotting within 30 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with cirrhosis to see how best to detect liver cancer early. If you qualify, you may receive regular monitoring that could help find liver cancer sooner, when treatment is more likely to work.
This study looks at tissue samples from people with bile duct, liver, or pancreas problems to develop better ways to detect cancers in these areas. If you are scheduled for a biopsy, scan, or surgery for a suspected growth in your liver, pancreas, or bile duct, you may be able to help.
This study follows people with bile duct cancer or certain liver cancers to better understand their disease. You might be included if you meet the diagnosis and basic participation requirements.
This study is for people having liver cancer surgery. It will look at certain fats in your blood to see if they can help doctors understand and track liver cancer better.
This trial tests a new blood test to help detect liver cancer (HCC) or confirm it’s not present in people with cirrhosis who are being monitored. It may help improve how doctors screen for liver cancer and decide who needs further imaging or treatment.
This study looks at what drives non-alcoholic fatty liver disease and how it affects the body, including immune-related changes. You may be invited if you have confirmed fatty liver disease or, alternatively, if you are a healthy person with no liver disease.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.